MIEF1 Antibody

What applications are MIEF1 antibodies most commonly used for in research?

MIEF1 antibodies are primarily used for Western blotting, immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry (IHC), flow cytometry (FCM), and ELISA. According to available product data, most commercial MIEF1 antibodies are validated for Western blot applications, with many also suitable for IF and IHC-p (paraffin-embedded sections) . When selecting an antibody, verify the applications it has been validated for, as not all antibodies perform consistently across all techniques.

What is the optimal protocol for visualizing MIEF1 localization through immunofluorescence?

For optimal MIEF1 visualization through IF:

• Fix cells with 4% paraformaldehyde (15 minutes, room temperature)

• Permeabilize with 0.2% Triton X-100 in PBS (10 minutes)

• Block with 5% normal serum in PBS (1 hour)

• Incubate with primary MIEF1 antibody (1:100-1:500 dilution, typically overnight at 4°C)

• Wash extensively with PBS (3 × 5 minutes)

• Incubate with fluorescent secondary antibody (1-2 hours, room temperature)

• Counterstain mitochondria with MitoTracker before fixation for co-localization studies

MIEF1 typically appears as punctate structures on the mitochondrial outer membrane, often co-localizing with mitochondrial markers and Drp1 puncta .

How can I determine the specificity of my MIEF1 antibody?

To validate MIEF1 antibody specificity:

• Perform Western blot analysis looking for a single band at approximately 51-52 kDa (endogenous MIEF1) or ~56 kDa (tagged MIEF1-V5)

• Include positive controls (tissues with known MIEF1 expression like heart, skeletal muscle, pancreas, and kidney)

• Use MIEF1 knockout or knockdown cell lines as negative controls

• Perform peptide competition assays with the immunizing peptide

• Compare results from multiple MIEF1 antibodies targeting different epitopes

• Verify through immunoprecipitation followed by mass spectrometry

How do I optimize co-immunoprecipitation protocols to study MIEF1 interactions with Drp1 and mitofusins?

For studying MIEF1 protein interactions:

• Chemical crosslinking approach:

  • Treat cells with 1 mM DSS (disuccinimidyl suberate) for 3 hours at room temperature before lysis

  • This preserves transient interactions and oligomeric states

  • Particularly important for capturing MIEF1-Drp1 complexes

• Standard co-IP without crosslinking:

  • Use mild lysis buffers containing 0.5-1% NP-40 or Triton X-100

  • Include protease inhibitors and phosphatase inhibitors

  • Maintain samples at 4°C throughout

• Antibody selection considerations:

  • Pre-conjugated V5 or Myc beads work well for tagged constructs

  • For endogenous IP, use 2 μg of anti-MIEF1 antibody pre-conjugated to Protein G beads

• Controls to include:

  • IgG control IP

  • Input sample (5-10% of lysate)

  • Negative control protein (e.g., VDAC1 was used as a mitochondrial outer membrane protein control)

The interaction between MIEF1 and Drp1 is robust and readily detectable by co-IP, whereas interactions with mitofusins (Mfn1/2) may require crosslinking for optimal detection .

What are the critical considerations when designing experiments to study MIEF1 oligomerization states?

MIEF1 forms oligomeric structures critical for its function. To study these:

• Non-reducing SDS-PAGE analysis:

  • V5-tagged MIEF1 appears as two bands under non-reducing conditions (~110 kDa and ~56 kDa)

  • Under reducing conditions, only the monomeric form (~56 kDa) is observed

• Chemical crosslinking approach:

  • Use membrane-permeable crosslinkers like DSS (1 mM)

  • Incubate intact cells with crosslinker (3 hours, room temperature)

  • Multiple high molecular weight bands will appear in immunoblotting

  • Compare crosslinked and non-crosslinked samples side by side

• Analysis of oligomeric mutants:

  • The C-terminal domain (residues 431-463) and region 160-169 affect MIEF1 oligomerization

  • Deletion mutants (e.g., MIEF1 Δ431-463, MIEF1 Δ160-169) can be used to study the functional consequences of disrupted oligomerization

• Disease-associated variants:

  • Variants like p.R169W and p.A53V alter the dimer/higher molecular weight oligomer ratio

  • Quantify the dimer/HMW ratio through densitometry for comparative analysis

How can I differentiate between the functions of MIEF1 (MID51) and its paralog MIEF2 (MID49) experimentally?

To distinguish between MIEF1 and MIEF2 functions:

• Selective knockout/knockdown approaches:

  • Generate single knockouts using CRISPR/Cas9 or siRNA-mediated knockdown

  • Create double knockouts to assess redundancy and compensatory effects

  • MIEF1 knockdown alone causes mitochondrial fragmentation (~80% of cells show fragmented phenotype)

• Rescue experiments:

  • Re-express one protein in the double knockout background

  • Use MIEF1/2-/- 293T cells as a validated model system

• Domain-specific analysis:

  • MIEF1 has distinct binding regions for Drp1, Mfn1, and Mfn2

  • MIEF1 Δ160-169 abolishes Drp1 binding but retains mitofusin binding

  • MIEF2 has different binding characteristics - deletion of the C-terminal region has less impact on Mfn1/2 binding compared to MIEF1

• Oligomerization differences:

  • MIEF2-mediated mitochondrial accumulation of Drp1 more effectively facilitates Drp1 oligomerization compared to MIEF1

  • Use in vivo chemical crosslinking to compare the extent of oligomerization

Why might MIEF1 antibody staining show diffuse cytoplasmic pattern instead of mitochondrial localization?

Several factors can cause diffuse versus mitochondrial-specific staining:

• Technical considerations:

  • Fixation method - overfixation can mask epitopes; try 4% PFA for 10-15 minutes

  • Permeabilization - excessive detergent can disrupt mitochondrial structure

  • Antibody incubation time - longer incubation at 4°C often yields better signal-to-noise ratio

• Biological considerations:

  • The N-terminal domain (residues 1-48) contains the transmembrane domain required for mitochondrial localization

  • The cytosolic mutant MIEF1 Δ1-48 shows diffuse cytoplasmic localization

  • Confirm mitochondrial targeting by co-staining with mitochondrial markers (Tom20, Tim23)

• Sample preparation:

  • Mitochondrial integrity may be compromised during processing

  • Fresh samples generally yield better results than stored samples

  • Consider using mitochondrial fractionation controls to verify antibody specificity

How can I resolve the issue of multiple bands appearing in Western blots with MIEF1 antibodies?

Multiple bands in MIEF1 Western blots can indicate:

• Oligomeric states:

  • Under non-reducing conditions, MIEF1 appears as both monomer (~52-56 kDa) and dimer (~110 kDa)

  • Running parallel samples with and without reducing agents can confirm

• Post-translational modifications:

  • MIEF1 undergoes ubiquitination during apoptosis and is degraded via the ubiquitin-proteasome system

  • Higher molecular weight smears may represent ubiquitinated forms

• Cross-reactivity:

  • Antibodies may detect both MIEF1 and its paralog MIEF2

  • Include MIEF1 knockout controls

  • Compare with antibodies targeting different epitopes

• Protocol optimization:

  • Increase blocking time/concentration to reduce non-specific binding

  • Optimize primary antibody dilution (typically 1:500-1:1000)

  • Include protease inhibitors in lysate preparation

How can MIEF1 antibodies be used to study disease mechanisms in neurodegenerative disorders?

MIEF1 has been implicated in neurodegenerative diseases, particularly Parkinson's disease:

• Analysis of patient samples:

  • Compare MIEF1 expression levels between patient and control brain tissues

  • Examine MIEF1 oligomerization states in patient-derived samples

  • MIEF1 variants p.R169W and p.A53V have been identified in early-onset Parkinson's disease patients

• MIEF1 variant characterization:

  • Generate cell lines expressing disease-associated variants (p.R169W, p.A53V)

  • Use MIEF1 antibodies to assess:

    • Protein stability and expression levels

    • Subcellular localization

    • Interaction with Drp1 and mitofusins

    • Oligomerization patterns (decreased dimer formation, increased HMW oligomers)

• Mitochondrial quality control studies:

  • Assess PINK1-PRKN-mediated mitophagy in MIEF1-deficient cells

  • MIEF1 deficiency impairs mitochondrial respiration and induces oxidative stress

  • MIEF1 loss sensitizes cells to BAX-mediated apoptosis

• Therapeutic target potential:

  • Screen for compounds that normalize MIEF1 oligomerization in disease models

  • Evaluate mitochondrial morphology following treatment

What experimental approaches can resolve contradictory findings regarding MIEF1's role in mitochondrial dynamics?

MIEF1 has paradoxical effects on mitochondrial dynamics, promoting both fission and fusion under different conditions:

• Expression level analysis:

  • Compare low versus high expression levels

  • Establish dose-response relationships using inducible expression systems

  • At high levels, MIEF1 sequesters Drp1 in an inactive state, inhibiting fission

• Time-course experiments:

  • Monitor mitochondrial morphology changes over time following MIEF1 manipulation

  • Use live-cell imaging with fluorescently tagged MIEF1 and mitochondrial markers

• Context-dependent function:

  • Evaluate MIEF1 function under different cellular stresses

  • During apoptosis, MIEF1 is degraded via UPS, affecting mitochondrial dynamics

  • Under basal versus CCCP-induced mitochondrial damage conditions

• Interaction partner analysis:

  • Map the protein interactome of MIEF1 under different conditions

  • MIEF1 interactions with Drp1 states vary based on Drp1 oligomerization status

  • Compare wild-type versus mutant MIEF1 interactomes

How can I design experiments to study the molecular details of MIEF1-Drp1 interaction using antibody-based approaches?

To dissect the molecular mechanisms of MIEF1-Drp1 interaction:

• Structure-function analysis:

  • Use antibodies recognizing different MIEF1 epitopes to map interaction domains

  • Key regions in MIEF1 for Drp1 binding include:

    • Residues 160-169 (critical for binding)

    • C-terminal domain (residues 431-463) (contributes to binding)

• Drp1 oligomerization state analysis:

  • MIEF1 interacts with a wider range of Drp1 assembly subunits compared to Mff

  • Use chemical crosslinking followed by immunoprecipitation to capture different oligomeric states

  • Compare wild-type Drp1 with oligomerization-defective mutants (K668E, 4A, A395D)

• Sequential immunoprecipitation approach:

  • First IP for MIEF1, then re-IP for specific Drp1 oligomeric forms

  • Alternatively, IP for Drp1, then re-IP for MIEF1

• Post-translational modification analysis:

  • Investigate how phosphorylation of Drp1 affects MIEF1 binding

  • Use phospho-specific antibodies against Drp1 after MIEF1 immunoprecipitation

How should researchers interpret changes in MIEF1 expression patterns across different tissues and experimental conditions?

When analyzing MIEF1 expression patterns:

• Tissue-specific considerations:

  • MIEF1 is highly expressed in heart, skeletal muscle, pancreas, and kidney

  • Expression levels vary across cell lines

  • Compare relative expression using housekeeping gene normalization

• Subcellular localization analysis:

  • MIEF1 localizes to mitochondrial outer membrane

  • Fractionation studies should include both cytosolic and mitochondrial markers (Tom20, Tim23, VDAC1)

  • Alterations in localization may indicate mitochondrial dysfunction

• Interpretation of knockdown/knockout effects:

  • MIEF1 depletion leads to mitochondrial fragmentation (~80% of cells)

  • Consider compensatory upregulation of MIEF2 or other fission/fusion proteins

  • Assess Drp1 recruitment/distribution by immunofluorescence

• Disease state analysis:

  • Changes in MIEF1 expression may indicate altered mitochondrial dynamics

  • Correlate with markers of mitochondrial function (membrane potential, respiration)

  • Consider bioenergetic profile changes using Seahorse analysis

What statistical approaches are most appropriate for quantifying changes in mitochondrial morphology following MIEF1 manipulation?

For rigorous quantification of mitochondrial morphology:

• Morphological parameter measurements:

  • Form factor (perimeter²/4π×area) - measure of mitochondrial complexity

  • Aspect ratio (major axis/minor axis) - measure of mitochondrial elongation

  • Branch length and number of branches

• Classification approaches:

  • Categorize cells into morphology groups (tubular, intermediate, fragmented)

  • Report percentages in each category across conditions

  • Typically >300 cells should be analyzed per condition across 3+ independent experiments

• Statistical analysis:

  • For categorical data: Chi-square test

  • For continuous morphological parameters: ANOVA with appropriate post-hoc tests

  • For time-course experiments: Repeated measures ANOVA

• Blinded analysis:

  • Observers should be blinded to experimental conditions

  • Multiple trained observers should independently score a subset of images to establish inter-observer reliability

  • Consider automated image analysis algorithms for unbiased quantification

How can MIEF1 antibodies be utilized in studying the crosstalk between mitochondrial dynamics and mitophagy?

MIEF1 plays roles in both mitochondrial dynamics and mitophagy:

• Sequential immunostaining approach:

  • Track MIEF1 colocalization with mitophagy markers (PINK1, Parkin, LC3)

  • MIEF1 deficiency sensitizes cells to PINK1-PRKN-mediated mitophagy

  • Monitor temporal relationship between MIEF1 degradation and mitophagy initiation

• Proximity labeling techniques:

  • BioID or APEX2 fused to MIEF1 to identify proximity partners during mitophagy

  • Validate interactions with co-IP using MIEF1 antibodies

  • Map dynamic interaction changes during mitophagy progression

• Mitochondrial subpopulation analysis:

  • Use magnetic immunocapture with MIEF1 antibodies to isolate MIEF1-enriched mitochondrial subpopulations

  • Compare protein composition and functional parameters with bulk mitochondria

• Ubiquitination dynamics:

  • MIEF1 degradation during apoptosis occurs via the ubiquitin-proteasome system

  • Track ubiquitinated forms using MIEF1 immunoprecipitation followed by ubiquitin immunoblotting

What experimental design would best address the potential role of MIEF1 in neurodegenerative diseases?

To investigate MIEF1's role in neurodegeneration:

• Patient-derived models:

  • iPSC-derived neurons from patients with MIEF1 variants (p.R169W, p.A53V)

  • Compare mitochondrial morphology, distribution, and function with control neurons

  • Assess susceptibility to neurotoxic insults

• In vivo approaches:

  • Generate MIEF1 knockin mouse models harboring disease-associated variants

  • Perform behavioral, histological, and biochemical analyses

  • Use MIEF1 antibodies for tissue immunostaining and biochemical characterization

• Therapeutic intervention testing:

  • Screen compounds that normalize mitochondrial dynamics in MIEF1-deficient models

  • Evaluate effects on neuronal survival and function

  • Track MIEF1 expression, localization, and interactions as pharmacodynamic markers

• Systems biology approach:

  • Integrate transcriptomic, proteomic, and metabolomic data from MIEF1 variant models

  • Identify dysregulated pathways and potential compensatory mechanisms

  • Validate key nodes using MIEF1 antibody-based approaches

How can researchers distinguish between direct effects of MIEF1 on mitochondrial dynamics versus indirect effects through interaction partners?

To differentiate direct versus indirect MIEF1 effects:

• Structure-function approach:

  • Use separation-of-function mutants:

    • MIEF1 Δ160-169 (abolishes Drp1 binding)

    • MIEF1 Δ431-463 (reduces Drp1 binding)

    • Map differential effects on mitochondrial morphology and function

• Temporal analysis:

  • Employ acute protein inactivation techniques (e.g., auxin-inducible degron)

  • Track the sequence of events following MIEF1 inactivation

  • Monitor interaction partner redistribution using immunofluorescence

• Reconstitution experiments:

  • In vitro reconstitution with purified components

  • Test direct effects on Drp1 GTPase activity and oligomerization

  • Use antibodies to immunodeplete specific factors from reconstitution assays

• Comparative paralog analysis:

  • Compare MIEF1 versus MIEF2 effects and interaction networks

  • Identify unique versus shared functions through differential antibody staining patterns

  • Create chimeric proteins to map domain-specific functions